{
    "organizations": [],
    "uuid": "4a09dd3e945d9af4fd0b51b355ec9d837a99218d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-nemaura-expands-manufacturing-capa/brief-nemaura-expands-manufacturing-capabilities-for-sugarbeat-commercial-launch-idUSFWN1QJ1AS",
    "ord_in_thread": 0,
    "title": "Nemaura Expands Manufacturing Capabilities For Sugarbeat Commercial Launch",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1 (Reuters) - Nemaura Medical Inc:\n* NEMAURA ANNOUNCES EXPANSION OF MANUFACTURING CAPABILITIES FOR SUGARBEAT® COMMERCIAL LAUNCH\n* NEMAURA MEDICAL INC - ‍SUGARBEAT IS EXPECTED TO LAUNCH INITIALLY IN UK UPON ACHIEVING CE APPROVAL, WHICH IS ANTICIPATED IN COMING MONTHS​\n* NEMAURA MEDICAL INC - ‍ADDITIONAL U.S. CLINICAL STUDIES TO FACILITATE FDA CLEARANCE ARE EXPECTED TO COMMENCE IN Q2​ Source text for Eikon:\n ",
    "published": "2018-03-02T05:22:00.000+02:00",
    "crawled": "2018-03-02T19:50:49.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "nemaura",
        "medical",
        "inc",
        "nemaura",
        "announces",
        "expansion",
        "manufacturing",
        "capability",
        "commercial",
        "launch",
        "nemaura",
        "medical",
        "inc",
        "expected",
        "launch",
        "initially",
        "uk",
        "upon",
        "achieving",
        "ce",
        "approval",
        "anticipated",
        "coming",
        "nemaura",
        "medical",
        "inc",
        "clinical",
        "study",
        "facilitate",
        "fda",
        "clearance",
        "expected",
        "commence",
        "source",
        "text",
        "eikon"
    ]
}